1609392-27-9

Usage

Uses

BMS-986165 is a novel oral selective TYK2 inhibitor with a unique mechanism of action that is expected to provide a promising oral option to help patients effectively manage their psoriasis.

Upstream product

• 22621-41-6 2-hydroxy-3-nitro-benzoic acid methyl ester 
• 90564-26-4 2-methoxy-3-nitro-benzoic acid methyl ester 
• 722538-98-9 2-methoxy-3-nitrobenzamide 
• 1609394-05-9 3-(2-methoxy-3-nitrophenyl)-4H-1,2,4-triazole 
• 1609394-08-2 3-(2-methoxy-3-nitrophenyl)-1-methyl-1H-1,2,4-triazole 
• 1609394-10-6 2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl) aniline 
• 85-38-1 3-nitrosalicylic acid 
• 6228-73-5 Cyclopropancarbamid 
• 1609394-23-1 6-chloro-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide 
• 1442437-21-9 4,6-dihydroxypyridazine-3-carboxylic acid 
• 105-50-0 diethyl 1,3-acetonedicarboxylate 
• 1609393-89-6 4,6-dichloro-N-trideuteromethylpyridazine-3 -carboxamide 
• 7436-22-8 methyl-d3-amine hydrochloride 
• 1352925-63-3 ethyl 4,6-dihydroxypyridazine-3-carboxylate 

Relevant academic research and scientific papers

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

Small molecule JAK inhibitors have emerged as a major therapeutic advancement in treating autoimmune diseases. The discovery of isoform selective JAK inhibitors that traditionally target the catalytically active site of this kinase family has been a formi

CRYSTALLINE FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE

Disclosed is crystalline Form B of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form B is the HCl salt of a neat crystalline form. Characterization data for Form B are disclosed.

PROCESS FOR THE PREPARATION OF 6-(CYCLOPROPANEAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-YL)PHENYL)AMINO)-N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE

The invention relates to an improved process for synthesizing 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide of the formula: [INSERT CHEMICAL STRUCTURE HERE] Compound I is currently in clinical trials for the treatment of auto-immune and auto-inflammatory diseases such as psoriasis.

AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES

Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.